Next Article in Journal
SARS-CoV-2 mRNA Vaccines Induce Cross-Reactive Antibodies to NL63 Coronavirus but Do Not Boost Pre-Existing Immunity Anti-NL63 Antibody Responses
Next Article in Special Issue
COVALENCE STUDY: Immunogenicity and Reactogenicity of a COVID-19 mRNA Vaccine in an Open-Label Cohort of Long-Survivor Patients with Metastatic Lung Cancer
Previous Article in Journal
Synthetic rEg.P29 Peptides Induce Protective Immune Responses Against Echinococcus granulosus in Mice
Previous Article in Special Issue
Simian Immunodeficiency Virus-Based Virus-like Particles Are an Efficient Tool to Induce Persistent Anti-SARS-CoV-2 Spike Neutralizing Antibodies and Specific T Cells in Mice
 
 
Systematic Review

Article Versions Notes

Vaccines 2025, 13(3), 267; https://doi.org/10.3390/vaccines13030267
Action Date Notes Link
article xml file uploaded 4 March 2025 08:04 CET Original file -
article xml uploaded. 4 March 2025 08:04 CET Update https://www.mdpi.com/2076-393X/13/3/267/xml
article pdf uploaded. 4 March 2025 08:04 CET Version of Record https://www.mdpi.com/2076-393X/13/3/267/pdf
article supplementary file uploaded. 4 March 2025 08:04 CET - https://www.mdpi.com/2076-393X/13/3/267#supplementary
article html file updated 4 March 2025 08:06 CET Original file https://www.mdpi.com/2076-393X/13/3/267/html
Back to TopTop